Physician profile
Patrick C Elwood
NPI 1083672760
$5,111.95
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,260 · 2020: $565 · 2021: $898 · 2022: $332 · 2023: $57.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $2,684.70 | 2019 | |
| Eisai INC. | $358.39 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $347.45 | 2020-2021 | |
| Seagen INC. | $161.69 | 2019-2022 | |
| Celgene Corporation | $101.10 | 2019-2023 | Pomalyst |
| Amgen INC. | $97.98 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.22 | 2019-2021 | |
| Coherus Oncology, INC. | $83.33 | 2021-2022 | |
| Taiho Oncology, INC. | $80.82 | 2020-2021 | |
| Glaxosmithkline, LLC. | $77.85 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $77.40 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $66.38 | 2019-2021 | |
| Genzyme Corporation | $62.50 | 2020-2021 | |
| Exelixis INC. | $51.18 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $48.79 | 2020-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Elwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.